| Characteristic | Overall N = 331 |
negative N = 221 |
positive N = 111 |
p-value2 |
|---|---|---|---|---|
| Age at time of sample (years) | 75 (69, 79) | 75 (69, 78) | 77 (73, 81) | 0.3 |
| Female sex | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| Race | 0.3 | |||
| black/aa | 4 (12%) | 4 (18%) | 0 (0%) | |
| white | 29 (88%) | 18 (82%) | 11 (100%) | |
| Ethnicity | 0.3 | |||
| hispanic/latinx | 1 (3.0%) | 0 (0%) | 1 (9.1%) | |
| not hispanic/latinx | 32 (97%) | 22 (100%) | 10 (91%) | |
| Death | 11 (33%) | 9 (41%) | 2 (18%) | 0.3 |
| Prolonged immunosuppression | 18 (60%) | 10 (48%) | 8 (89%) | 0.049 |
| Number of non-HLA positive beads | 5 (1, 17) | 1 (1, 5) | 23 (15, 29) | 0.010 |
| Hypertension | 31 (94%) | 22 (100%) | 9 (82%) | 0.10 |
| Hyperlipidemia | 26 (79%) | 16 (73%) | 10 (91%) | 0.4 |
| Coronary artery disease | 23 (70%) | 13 (59%) | 10 (91%) | 0.11 |
| Diabetes mellitus | 8 (24%) | 7 (32%) | 1 (9.1%) | 0.2 |
| Heart failure | 11 (33%) | 7 (32%) | 4 (36%) | >0.9 |
| LGE burden, CMR (% LV mass) | 7 (0, 11) | 6 (0, 9) | 11 (4, 15) | 0.049 |
| LVEF, CMR (%) | 60 (54, 64) | 60 (53, 63) | 64 (58, 68) | 0.14 |
| RVEF, CMR (%) | 52 (48, 57) | 52 (48, 54) | 52 (45, 58) | 0.5 |
| LV wall thickness (AP), mm | 10.00 (7.00, 11.00) | 10.00 (8.00, 11.00) | 9.00 (6.00, 11.00) | >0.9 |
| LV wall thickness (PL), mm | 8.00 (7.00, 9.00) | 7.50 (6.00, 9.00) | 9.00 (7.00, 11.00) | 0.12 |
| Global radial strain, CMR (%) | 29 (22, 36) | 29 (22, 36) | 34 (22, 36) | 0.6 |
| Global circumferential strain, CMR (%) | -18.0 (-19.9, -14.6) | -17.9 (-20.3, -13.0) | -18.4 (-19.8, -14.8) | 0.8 |
| Global longitudinal strain (GLS), CMR (%) | -14.7 (-16.7, -11.3) | -14.7 (-17.9, -11.3) | -14.6 (-15.5, -10.8) | 0.7 |
| Abnormal GLS | 23 (82%) | 14 (82%) | 9 (82%) | >0.9 |
| 1 Median (Q1, Q3); n (%) | ||||
| 2 Wilcoxon rank sum test; NA; Fisher’s exact test | ||||